Craft

Intra-Cellular Therapies

Stock Price

$67.2

2024-05-31

Market Capitalization

$7.1 B

2024-05-31

Revenue

$464.4 M

FY, 2023

Intra-Cellular Therapies Summary

Company Summary

Overview
Intra-Cellular Therapies is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. Intra-Cellular Therapies is developing its lead drug candidate, lumateperone, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders.
Type
Public
Status
Active
Founded
2002
HQ
New York, NY, US | view all locations
Website
http://www.intracellulartherapies.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Sharon Mates, Founder, Chairman & Chief Executive Officer

    • Mark Neumann, Executive Vice President, Chief Commercial Officer

      • Richard Lerner, Director

        • Christopher Alafi, Director

          Operating MetricsView all

          Patents and Patent Applications

          80

          FY, 2017

          LocationsView all

          1 location detected

          • New York, NY HQ

            United States

            430 E 29th St #900

          Intra-Cellular Therapies Financials

          Summary Financials

          Revenue (Q1, 2024)
          $144.9M
          Net income (Q1, 2024)
          ($15.2M)
          Cash (Q1, 2024)
          $139.8M
          EBIT (Q1, 2024)
          ($21.0M)
          Enterprise value
          $7.0B

          Footer menu